Raymond James Financial’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Raymond James Financial’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$81.7M	Buy	516,322 +83,190	+19%	+$11.2M	0.02%	665
2026 Q1	$55.3M	Sell	433,132 -32,886	-7%	-$4.11M	0.02%	799
2025 Q4	$56.8M	Buy	466,018 +84,438	+22%	+$9.68M	0.02%	760
2025 Q3	$38.2M	Sell	381,580 -117,859	-24%	-$10.6M	0.01%	974
2025 Q2	$41.4M	Sell	499,439 -43,701	-8%	-$3.49M	0.01%	873
2025 Q1	$44M	Sell	543,140 -73,433	-12%	-$6.56M	0.02%	792
2024 Q4	$55.5M	Buy	+616,573	New	+$59.7M	0.02%	666

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Raymond James Financial's XBI Position: Q2 2026 in Review

Raymond James Financial increased its State Street SPDR S&P Biotech ETF (XBI) stake by 19% in Q2 2026, buying an estimated $11.2M and bringing the position to 516,322 shares worth $81.7M. The position accounts for 0.02% of the portfolio, ranked #665.

Raymond James Financial first reported a position in XBI in Q4 2024 and has held it in 7 quarters since. 936 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Raymond James Financial held 516,322 shares of State Street SPDR S&P Biotech ETF worth $81.7M as of Q2 2026.
Raymond James Financial bought 83,190 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $11.2M.
State Street SPDR S&P Biotech ETF made up 0.02% of Raymond James Financial's portfolio in Q2 2026, its #665 holding.
Raymond James Financial first reported a position in State Street SPDR S&P Biotech ETF in Q4 2024 and has held it in 7 quarters since.
936 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.